Meta-analysis: Effect of preoperative infliximab use on early postoperative complications in patients with ulcerative colitis undergoing abdominal surgery

Alimentary Pharmacology and Therapeutics

Volumn 36, Issue 10, 2012, Pages 922-928

  Yang, Z ^a   Wu, Q ^a   Wang, F ^b   Wu, K ^a   Fan, D ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b NINGXIA MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN A; INFLIXIMAB; MESALAZINE;

ABDOMINAL SURGERY; ARTICLE; COHORT ANALYSIS; DRUG EFFICACY; DRUG SAFETY; DRUG USE; HUMAN; META ANALYSIS; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; POSTOPERATIVE COMPLICATION; POSTOPERATIVE INFECTION; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; RISK ASSESSMENT; SURGICAL RISK; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; ULCERATIVE COLITIS;

ABDOMEN; ANTIBODIES, MONOCLONAL; CASE-CONTROL STUDIES; COLITIS, ULCERATIVE; GASTROINTESTINAL AGENTS; HUMANS; POSTOPERATIVE COMPLICATIONS; PREOPERATIVE PERIOD; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 84867577829     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12060     Document Type: Article

References (31)

1. Van Assche G, Vermeire S, Rutgeerts P,. Infliximab therapy for patients with inflammatory bowel disease: 10 years on. Eur J Pharmacol 2009; 623: S17-25.
2. Danese S, Fiocchi C,. Ulcerative colitis. N Engl J Med 2011; 365: 1713-25.
3. Domènech E, Zabana Y, Garcia-Planella E, et al,. Clinical outcome of newly diagnosed Crohn's disease: a comparative, retrospective study before and after infliximab availability. Aliment Pharmacol Ther 2010; 31: 233-9.
4. Yang Z, Wu Q, Wu K, Fan D,. Meta-analysis: pre-operative infliximab treatment and short-term post-operative complications in patients with ulcerative colitis. Aliment Pharmacol Ther 2010; 31: 486-92.
5. Mowat C, Cole A, Windsor A, et al,. Guidelines for the management of inflammatory bowel disease in adults. Gut 2011; 60: 571-607.
6. Kopylov U, Ben-Horin S, Zmora O, Eliakim R, Katz LH,. Anti-tumor necrosis factor and postoperative complications in Crohn's disease: systematic review and meta-analysis. Inflamm Bowel Dis 2012; doi: 10.1002/ibd.22954 [Epub ahead of print].
7. Wells GA, Shea B, O'Connell D, et al,. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analysis. Available at: http://www.ohri.ca/programs/clinical-epidemiology/oxford.htm.
8. Kunitake H, Hodin R, Shellito PC, Sands BE, Korzenik J, Bordeianou L,. Perioperative treatment with infliximab in patients with Crohn's disease and ulcerative colitis is not associated with an increased rate of postoperative complications. J Gastrointest Surg 2008; 12: 1730-6.
9. Regadas FSP, Pinto RA, Murad-Regadas SM, et al,. Short-term outcome of infliximab and other medications on patients with inflammatory bowel disease undergoing ileostomy reversal. Colorectal Dis 2011; 13: 555-60.
10. Rizzo G, Armuzzi A, Pugliese D, et al,. Anti-TNF-alpha therapies do not increase early postoperative complications in patients with inflammatory bowel disease. An Italian single-center experience. Int J Colorectal Dis 2011; 26: 1435-44.
11. Waterman M, Xu W, Dinani A, et al,. Preoperative biological therapy and short-term outcomes of abdominal surgery in patients with inflammatory bowel disease. Gut 2012; doi: 10.1136/gutjnl-2011-301495 [Epub ahead of print].
12. Järnerot G, Hertervig E, Friis-Liby I, et al,. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 2005; 128: 1805-11. (Pubitemid 40824691)
13. Selvasekar CR, Cima RR, Larson DW, et al,. Effect of infliximab on short-term complications in patients undergoing operation for chronic ulcerative colitis. J Am Coll Surg 2007; 204: 956-62. (Pubitemid 46661200)
14. Schluender SJ, Ippoliti A, Dubinsky M, et al,. Does infliximab influence surgical morbidity of ileal pouch-anal anastomosis in patients with ulcerative colitis? Dis Colon Rectum 2007; 50: 1747-53. (Pubitemid 350077092)
15. Mor IJ, Vogel JD, da Luz Moreira A, Shen B, Hammel J, Remzi FH,. Infliximab in ulcerative colitis is associated with an increased risk of postoperative complications after restorative proctocolectomy. Dis Colon Rectum 2008; 51: 1202-7.
16. Ferrante M, D'Hoore A, Vermeire S, et al,. Corticosteroids but not infliximab increase short-term postoperative infectious complications in patients with ulcerative colitis. Inflamm Bowel Dis 2009; 15: 1062-70.
17. Coquet-Reinier B, Berdah SV, Grimaud JC, et al,. Preoperative infliximab treatment and postoperative complications after laparoscopic restorative proctocolectomy with ileal pouch-anal anastomosis: a case-matched study. Surg Endosc 2010; 24: 1866-71.
18. Gainsbury ML, Chu DI, Howard LA, et al,. Preoperative infliximab is not associated with an increased risk of short-term postoperative complications after restorative proctocolectomy and ileal pouch-anal anastomosis. J Gastrointest Surg 2011; 15: 397-403.
19. de Silva S, Ma C, Proulx MC, et al,. Postoperative complications and mortality following colectomy for ulcerative colitis. Clin Gastroenterol Hepatol 2011; 9: 972-80.
20. Kennedy R, Potter DD, Moir C, Zarroug AE, Faubion W, Tung J,. Pediatric chronic ulcerative colitis: does infliximab increase post-ileal pouch anal anastomosis complications? J Pediatr Surg 2012; 47: 199-203.
21. Schaufler C, Lerer T, Campbell B, et al,. Pre-operative immunosuppression is not associated with increased post-operative complications following colectomy in children with colitis. J Pediatr Gastroenterol Nutr 2012; doi: 10.1097/MPG.0b013e318252c831 [Epub ahead of print].
22. Bregnbak D, Mortensen C, Bendtsen F,. Infliximab and complications after colectomy in patients with ulcerative colitis. J Crohns Colitis 2012; 6: 281-6.
23. NàrgÅrd BM, Nielsen J, Qvist N, Gradel KO, de Muckadell OB, Kjeldsen J,. Pre-operative use of anti-TNF-α agents and the risk of post-operative complications in patients with ulcerative colitis-a nationwide cohort study. Aliment Pharmacol Ther 2012; 35: 1301-9.
24. Eshuis EJ, Al SR, Stokkers PC, Ponsioen CY, Tanis PJ, Bemelman WA,. Previous infliximab therapy and postoperative complications after proctocolectomy with ileum pouch anal anastomosis. J Crohns Colitis 2012; doi: 10.1016/j.crohns.2012.03.013 [Epub ahead of print].
25. Fasanmade AA, Adedokun OJ, Ford J, et al,. Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis. Eur J Clin Pharmacol 2009; 65: 1211-28.
26. Cornillie F, Shealy D, D'Haens G, et al,. Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn's disease. Aliment Pharmacol Ther 2001; 15: 463-73. (Pubitemid 32242771)
27. Kasparek MS, Bruckmeier A, Beigel F, et al,. Infliximab does not affect postoperative complication rates in Crohn's patients undergoing abdominal surgery. Inflamm Bowel Dis 2012; 18: 1207-13.
28. Subramanian V, Saxena S, Kang JY, Pollok RC,. Preoperative steroid use and risk of postoperative complications in patients with inflammatory bowel disease undergoing abdominal surgery. Am J Gastroenterol 2008; 103: 2373-81.
29. Indar AA, Young-Fadok TM, Heppell J, Efron JE,. Effect of perioperative immunosuppressive medication on early outcome in Crohn's disease patients. World J Surg 2009; 33: 1049-52.
30. Ooi CJ, Fock KM, Makharia GK, et al,. The Asia-Pacific consensus on ulcerative colitis. J Gastroenterol Hepatol 2010; 25: 453-68.
31. Orlando A, Armuzzi A, Papi C, et al,. The Italian Society of Gastroenterology (SIGE) and the Italian Group for the study of Inflammatory Bowel Disease (IG-IBD) clinical practice guidelines: the use of tumor necrosis factor-alpha antagonist therapy in inflammatory bowel disease. Dig Liver Dis 2011; 43: 1-20.